Riskpilot← Back to searchSign inGet full accessSGPTH Life Science AB
ABActiveOrg 5591811327Valloxvägen 62All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20180 employees
Revenue 2025
SEK 142K
-29% vs 2024
EBITDA margin
-741.5%
+47% vs 2024
Equity ratio
94.9%
Financial strength
Net profit 2025
SEK -1,3M
+40% vs 2024
| Revenue | SEK 142K | -29% |
| EBITDA | SEK -1,1M | +47% |
| Net profit | SEK -1,3M | +40% |
| Total assets | SEK 2,4M | -35% |
| Equity | SEK 2,2M | -36% |
| Employees | 0 | — |
Legal name
SGPTH Life Science AB
Org number
5591811327
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
21 november 2018
Share capital
SEK 77 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Framtagande av antikroppar och peptider för diagnos, behandling, prognos av sjukdomar. Framtagande av olika diagnostiska metoder inom Life Science. Försäljning, marknadsföring och distribution av framtagna produkterna.
Address
Valloxvägen 62
Email
stina.ekman@arthrodiagnostics.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 200 | 142 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | −185 | −168 | −1 148 | −1 970 | −1 053 |
| Depreciation & amort. | −46 | −59 | −109 | −176 | −235 |
| EBIT | −231 | −227 | −1 257 | −2 145 | −1 288 |
| Net financials | — | — | 6 | 31 | 18 |
| Profit before tax | −231 | −227 | −1 251 | −2 114 | −1 270 |
| Tax | −0 | — | −0 | — | −0 |
| Net profit | −231 | −227 | −1 251 | −2 114 | −1 270 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 866 | 940 | 1 572 | 3 642 | 2 350 |
| Equity | 650 | 724 | 1 356 | 3 498 | 2 229 |
| Long-term debt | 0 | — | 0 | — | 0 |
| Short-term debt | 216 | 216 | 216 | 143 | 121 |
| Total debt | 216 | 216 | 216 | 143 | 121 |
EBITDA margin
-741.5%
This company
15.8%
Market median
-4793% vs market
20212025
Equity ratio
94.9%
This company
38.2%
Market median
+148% vs market
20212025
Return on equity
-57.0%
This company
18.4%
Market median
-410% vs market
20212025
Net profit margin
-894.4%
This company
8.1%
Market median
-11142% vs market
20212025
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20212025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EC Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SGPTH Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Carina Sternesjö | Audit | 0 companies |
| Inga Stina Ekman | Board of Directors | 0 companies |
| Eva S R Deijenberg Skiöldebrand | Board of Directors | 0 companies |
| Anders Harald Lindahl | Chairman | 0 companies |
| Viveka A M Sernvi Hansson | Board of Directors | 0 companies |